Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab

Ann Rheum Dis. 2018 Nov;77(11):1694-1695. doi: 10.1136/annrheumdis-2018-213496. Epub 2018 May 18.

Authors

Savino Sciascia^#¹, Elena Rubini^#¹, Massimo Radin¹, Irene Cecchi¹, Daniela Rossi¹, Dario Roccatello¹

Affiliation

¹ Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Turin, Italy.

^# Contributed equally.

PMID: 29776976
DOI: 10.1136/annrheumdis-2018-213496

No abstract available

Keywords: B cells; antiphospholipid antibodies; antiphospholipid syndrome; systemic lupus erythematosus; treatment.

Publication types

Letter

MeSH terms

Adult
Antibodies, Anticardiolipin / blood
Antibodies, Monoclonal, Humanized / therapeutic use*
Antiphospholipid Syndrome / drug therapy*
Autoantibodies / blood*
Female
Humans
Immunosuppressive Agents / therapeutic use*
Lupus Erythematosus, Systemic / drug therapy*
Male
Middle Aged
beta 2-Glycoprotein I / immunology

Substances

Antibodies, Anticardiolipin
Antibodies, Monoclonal, Humanized
Autoantibodies
Immunosuppressive Agents
beta 2-Glycoprotein I
belimumab